Siderosis

Weston A. Price Foundation Proposes Deeper Look Into the Cause of TB

Retrieved on: 
Friday, March 22, 2024
Chelation, Crimean War, Industrial Age, Periodic breathing, Health, Meat, Siderosis, Cough, Natural gas, TIME, Lactoferrin, Coal, Mycobacterium tuberculosis, Disease, Tuberculosis, Incidence, Anglo-French Wars, Iron, Research, Mystery, Weston A. Price Foundation, Stainless steel, Death, Human, Bacillus, IRON, Atmosphere, Vaccination, Industrialisation, Contagious disease, TB, Power, Aluminium, Multimedia, Blood

DALLAS, March 22, 2024 /PRNewswire/ -- World TB Day, March 24, commemorates the date in 1882 when Dr. Robert Koch announced his discovery of Mycobacterium tuberculosis, the bacillus believed to cause tuberculosis (TB). Koch argued that TB is a contagious disease, spreading from one person to the next through the air. Based on the notion that TB is caused by a contagious bacterium, conventional treatment for TB involves vaccination and administration of multiple antibiotics over a long period. New information requires the scientific community to reexamine the reigning theories about tuberculosis.

Key Points: 
  • DALLAS, March 22, 2024 /PRNewswire/ -- World TB Day, March 24, commemorates the date in 1882 when Dr. Robert Koch announced his discovery of Mycobacterium tuberculosis , the bacillus believed to cause tuberculosis (TB).
  • Koch argued that TB is a contagious disease, spreading from one person to the next through the air.
  • "We propose looking elsewhere for the cause of TB," says Sally Fallon Morel of the Weston A.
  • "We propose looking elsewhere for the cause of this terrible illness," says Sally Fallon Morell, president of the Weston A.

Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’s Disease

Retrieved on: 
Wednesday, December 20, 2023
Quality of life, MRI, Hippocampus, Hypoplastic left heart syndrome, Diffusion MRI, Neuron, Disease, Brain, Incidence, Hypersensitivity, Magnetic resonance imaging, CLEAR, Week, Mini–Mental State Examination, Dementia, Degree, Atrophy, TBV, EKG, DTI, Patient, Thalamus, Magnetic resonance, Safety, Siderosis, HLHS, Alzheimer's disease, Medical imaging

The expanded data set reinforced the earlier top-line findings showing that the primary safety endpoint was met and provided further support for Lomecel-B’s positive benefit/risk profile.

Key Points: 
  • The expanded data set reinforced the earlier top-line findings showing that the primary safety endpoint was met and provided further support for Lomecel-B’s positive benefit/risk profile.
  • Wa’el Hashad, CEO of Longeveron, commented: “These new data support our initial results for CLEAR MIND that we announced in October and provide further validation of both the safety and therapeutic potential of Lomecel-B™ in the treatment of mild Alzheimer’s disease.
  • In addition to these clinical findings, brain imaging showed improvement in brain architecture measured by volumetric MRI and DTI, respectively.
  • Taken together, the Company believes the results of the CLEAR MIND study build a strong foundation for further development in mild Alzheimer's disease patients.

Lecanemab named one of the world's best inventions in 2023 by TIME

Retrieved on: 
Tuesday, October 24, 2023
Risk, Aneurysm, Vomiting, Cerebral edema, Focal neurologic signs, Incidence, Dementia, Nausea, Disease, Intraparenchymal hemorrhage, Intracerebral hemorrhage, CET, Chills, AI, Paracetamol, Hypersensitivity, Memory, Lecanemab, Vascular malformation, MRI, Excipient, Neuroimaging, Fatal, Thought, Dizziness, Aspirin, Edema, Anticoagulant, Cerebral amyloid angiopathy, Magnetic resonance imaging, Patient, Bronchospasm, Alzheimer's disease, Anaphylaxis, Genetic testing, TIME, ARIA, Arthralgia, Research, Eisai, Fever, Hypotension, Amyloid, Headache, Siderosis, Behavior, Invention, Observation, Hypertension, Confusion, Seizure, Angioedema, Status epilepticus, Tissue plasminogen activator, Pharmaceutical industry, Lace, Medical imaging, Copper

"It is a great honor and tremendous recognition that lecanemab is included in TIME's list of the world's best inventions this year.

Key Points: 
  • "It is a great honor and tremendous recognition that lecanemab is included in TIME's list of the world's best inventions this year.
  • TIME's annual list of the best inventions includes "200 extraordinary innovations changing lives."
  • The information was released for public disclosure, through the agency of the contact persons below, on October 24, 2023, at 4.50 p.m. CET.
  • ARIA usually occurs early in treatment and is usually asymptomatic, although serious and life-threatening events rarely can occur.

LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan

Retrieved on: 
Monday, September 25, 2023
Hypersensitivity, Status epilepticus, Intracerebral hemorrhage, Cerebral amyloid angiopathy, Arthralgia, Cerebral edema, Hypotension, Aneurysm, Risk, Focal neurologic signs, Chills, Fatal, Fever, Edema, Neuroimaging, AND, Angioedema, Siderosis, Tissue plasminogen activator, Aspirin, Hypertension, Vomiting, Incidence, Excipient, ARIA, Anticoagulant, MRI, Magnetic resonance imaging, Dizziness, Amyloid, Patient, Intraparenchymal hemorrhage, Anaphylaxis, Paracetamol, Seizure, Genetic testing, Confusion, Nausea, Observation, Lecanemab, Headache, Bronchospasm, Vascular malformation, Medical device, Pharmaceutical industry, Lace, Medical imaging, Copper

INDICATION, DOSAGE AND ADMINISTRATION, AND IMPORTANT SAFETY INFORMATION IN THE U.S.

Key Points: 
  • INDICATION, DOSAGE AND ADMINISTRATION, AND IMPORTANT SAFETY INFORMATION IN THE U.S.
    LEQEMBI is indicated for the treatment of Alzheimer’s disease.
  • Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.
  • ARIA usually occurs early in treatment and is usually asymptomatic, although serious and life-threatening events rarely can occur.
  • Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA.

"LEQEMBI Intravenous Infusion" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Japan

Retrieved on: 
Monday, September 25, 2023
Amyloid-related imaging abnormalities, PMID, Outline, Clinical trial, Marketing, The New England Journal of Medicine, Deficit spending, Pathology, Ministry of Health, Labour and Welfare, Research, Brain, Siderosis, History, MCI, The Different Forms of Flowers on Plants of the Same Species, Clarity, Ministry, ARIA, Dementia, HIV disease progression rates, Patient, Immunoglobulin G, Superficial siderosis, PLOS One, Co-promotion, Ministry of Health (Kuwait), Therapy, Headache, Neurotoxicity, Disease, ADCS, Pharmaceutical industry, Alzheimer's disease, Biogen, Amyloid beta, Health, Eisai

Japan is the second country to grant approval, following the traditional approval in the U.S. in July 2023.

Key Points: 
  • Japan is the second country to grant approval, following the traditional approval in the U.S. in July 2023.
  • In the Clarity AD clinical trial, treatment with LEQEMBI reduced clinical decline on CDR-SB by 27% at 18 months compared to placebo.
  • "Today LEQEMBI received approval, making it the first approved anti-amyloid Alzheimer's disease treatment shown to reduce the rate of disease progression and to slow cognitive impairment in the early and mild dementia stages of the disease in Japan.
  • In Japan, Eisai and Biogen Japan will co-promote LEQEMBI, with Eisai distributing the product as the Marketing Authorization Holder.

Alzheon to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet ALZ-801 (Valiltramiprosate) and Positive Biomarker/Clinical Correlations from Phase 2 Biomarker Study at AAIC in Amsterdam

Retrieved on: 
Tuesday, July 11, 2023
Research, Other Health, General Health, Pharmaceutical, Biometrics, Mental Health, Clinical Trials, Science, Neurology, Biotechnology, FDA, Health, Other Science, Genotype, Atrophy, MH, Cerebral amyloid angiopathy, CAA, Prevalence, Pathology, NDA, Black box, COVID, Siderosis, Biomarker, MCI, Doctor of Philosophy, Female, Mild, Common, Blood, Plasma, MRI, Alzheimer's disease, ARIA, Occipital bone, Magnetic resonance imaging, Cortex, MD, Patient, Risk, Horseshoe kidney, CEST, Lateral ventricles, Composite, Medicine, Drug development, Oral, AD, Cerebral edema, MMSE, Conference, Neurotoxicity, Safety, Disease, Pharmaceutical industry, Medical imaging, APOE4, Alzheon, Early

ALZ-801 (valiltramiprosate) is an investigational oral disease-modifying therapy in Phase 3 development for the treatment of Early AD.

Key Points: 
  • ALZ-801 (valiltramiprosate) is an investigational oral disease-modifying therapy in Phase 3 development for the treatment of Early AD.
  • In mechanism-of-action studies, ALZ-801 fully blocked the formation of neurotoxic soluble beta amyloid (Aβ) oligomers at the Phase 3 clinical dose.
  • This population is the focus of Alzheon’s pivotal Phase 3 APOLLOE4 trial , which is now fully enrolled and will be completed in the third quarter of 2024.
  • We look forward to communicating the final 24-month data from our Phase 2 study later in 2023.”

Alzheon to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet ALZ-801 (Valiltramiprosate) and Results of Phase 2 Biomarker Study at American Academy of Neurology Conference in Boston

Retrieved on: 
Tuesday, April 18, 2023
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Mitt, MH, CAA, Cerebral amyloid angiopathy, Cerebral edema, AAN, Pathology, NDA, American Academy, EST, COVID, Siderosis, Inflammation, MCI, Doctor of Philosophy, Neurotoxicity, Common, Blood, Biomarker, Plasma, ARIA, Occipital bone, Amyloid, MD, ADNI, Patient, Risk, Composite, Prevalence, Oral, Microglia, AD, Safety, MMSE, Conference, Female, American Academy of Neurology, Disease, Pharmaceutical industry, Medical imaging, APOE4, Alzheon

ALZ-801 (valiltramiprosate) is an investigational oral disease-modifying therapy in Phase 3 development for the treatment of early AD.

Key Points: 
  • ALZ-801 (valiltramiprosate) is an investigational oral disease-modifying therapy in Phase 3 development for the treatment of early AD.
  • In mechanism-of-action studies, ALZ-801 fully blocked the formation of neurotoxic soluble beta amyloid (Aβ) oligomers at the Phase 3 clinical dose.
  • This population is the focus of Alzheon’s pivotal Phase 3 APOLLOE4 trial , which is now fully enrolled and will be completed in mid-2024.
  • We look forward to communicating the final 24-month data from our Phase 2 study later in 2023.”

BioArctic: New lecanemab-data presented at the AD/PD™ 2023 conference

Retrieved on: 
Monday, April 3, 2023
Amyloid-related imaging abnormalities, Anticoagulant, Apolipoprotein E, Genotype, Intracerebral hemorrhage, CET, Clinical trial, The New England Journal of Medicine, Edema, DSM-IV codes, Horseshoe kidney, Siderosis, Quality, Science, Clarity, Eisai, Aria, Incidence, ARIA, Dementia, QOL, International Conference on Population and Development, Lecanemab, HIV disease progression rates, Patient, Randomness, Quality of life (healthcare), Quality of life, Co-promotion, 2023 International Conference on Climate Resilient Pakistan, Conference, Pharmaceutical industry, Alzheimer's disease, Biogen

Lecanemab met the primary endpoint and all key secondary endpoints with highly statistically significant results.

Key Points: 
  • Lecanemab met the primary endpoint and all key secondary endpoints with highly statistically significant results.
  • In November 2022, results of the Clarity AD study were presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference and simultaneously published in the peer-reviewed medical journal, The New England Journal of Medicine .
  • His presentation concluded that lecanemab has a unique binding profile, with strong selectivity for protofibrils over monomers and fibrils of Aβ.
  • The information was released for public disclosure, through the agency of the contact person below, on April 3, 2023, at 08:00 a.m. CET.

BioArctic: New lecanemab-data presented at the AD/PD™ 2023 conference

Retrieved on: 
Monday, April 3, 2023
Amyloid-related imaging abnormalities, Anticoagulant, Apolipoprotein E, Genotype, Intracerebral hemorrhage, CET, Clinical trial, The New England Journal of Medicine, Edema, DSM-IV codes, Horseshoe kidney, Siderosis, Quality, Science, Clarity, Eisai, Aria, Incidence, ARIA, Dementia, QOL, International Conference on Population and Development, Lecanemab, HIV disease progression rates, Patient, Randomness, Quality of life (healthcare), Quality of life, Co-promotion, 2023 International Conference on Climate Resilient Pakistan, Conference, Pharmaceutical industry, Alzheimer's disease, Biogen

Lecanemab met the primary endpoint and all key secondary endpoints with highly statistically significant results.

Key Points: 
  • Lecanemab met the primary endpoint and all key secondary endpoints with highly statistically significant results.
  • In November 2022, results of the Clarity AD study were presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference and simultaneously published in the peer-reviewed medical journal, The New England Journal of Medicine .
  • His presentation concluded that lecanemab has a unique binding profile, with strong selectivity for protofibrils over monomers and fibrils of Aβ.
  • The information was released for public disclosure, through the agency of the contact person below, on April 3, 2023, at 08:00 a.m. CET.

EISAI PRESENTED NEW ANALYSES OF ARIA AND QOL ON LECANEMAB IN CLARITY AD AT THE AD/PD™ 2023 ANNUAL MEETING

Retrieved on: 
Friday, March 31, 2023
Amyloid-related imaging abnormalities, Anticoagulant, Apolipoprotein E, Intracerebral hemorrhage, Disease, Alzheimer's disease, Clinical trial, The New England Journal of Medicine, Overalls, BIIB, Quality of life, Horseshoe kidney, Siderosis, Quality, ARIA-H, The Different Forms of Flowers on Plants of the Same Species, Incidence, QOL, Dementia, ARIA, International Conference on Population and Development, Patient, Headquarters, Randomness, Corporation, Quality of life (healthcare), Co-promotion, 2023 International Conference on Climate Resilient Pakistan, Caregiver burden, Conference, Pharmaceutical industry, Biogen, Lecanemab, Clarity, Eisai

Clarity AD was a global confirmatory Phase 3 placebo-controlled, double-blind, parallel-group, randomized study in 1,795 people with early Alzheimer's disease (AD) (lecanemab group: 10 mg/kg bi-weekly IV treatment: 898, placebo group: 897).

Key Points: 
  • Clarity AD was a global confirmatory Phase 3 placebo-controlled, double-blind, parallel-group, randomized study in 1,795 people with early Alzheimer's disease (AD) (lecanemab group: 10 mg/kg bi-weekly IV treatment: 898, placebo group: 897).
  • Lecanemab Phase 3 Clarity AD Trial: ARIA With the Use of Antiplatelets or Anticoagulants in Early Alzheimer's Disease
    In the Clarity AD study, ARIA rates were higher for patients receiving lecanemab compared to those on placebo.
  • In Clarity AD, the pattern of occurrence of isolated ARIA-H in lecanemab group was similar to that in placebo group.
  • The results of the Clarity AD Health-related QoL measures presented additional evidence for meaningful benefits of lecanemab treatment to patients and care partners.